| 2022-08-02 | +39.9% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2023-08-01 | +38.0% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2025-07-09 | +35.8% | legal | SEC EDGAR | RYTM 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-07-09 | +35.8% | news | Investor's Business Daily | Biotech Hits Record High On 'Impressive' Results For Obesity Drug - Investor's Business Daily |
| 2025-04-07 | +24.7% | legal | SEC EDGAR | RYTM 8-K: 7.01, 8.01 (SEC Filing) |
| 2022-03-01 | +21.0% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2021-08-03 | -20.6% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2022-09-15 | -19.2% | legal | SEC EDGAR | RYTM 8-K: 8.01 and (SEC Filing) |
| 2022-06-16 | +17.7% | legal | SEC EDGAR | RYTM 8-K: 1.01 and 2.03 (SEC Filing) |
| 2022-05-03 | -16.1% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2024-11-05 | +14.5% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2021-11-02 | +13.4% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2025-11-04 | -11.7% | earnings | Seeking Alpha | Rhythm Pharmaceuticals reports mixed Q3 results; updates FY25 outlook |
| 2025-11-04 | -11.7% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2025-11-04 | -11.7% | earnings | Yahoo Finance | Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance |
| 2024-05-07 | -11.4% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2026-03-31 | +10.4% | news | Motley Fool | Is This Weight Loss Drug Stock a Buy After a New Approval? |
| 2026-03-31 | +10.4% | earnings | MarketBeat | Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading 10.9% Higher - Should You Buy? - MarketBeat |
| 2026-03-31 | +10.4% | news | The Motley Fool | Is This Weight Loss Drug Stock a Buy After a New Approval? - The Motley Fool |
| 2026-03-31 | +10.4% | news | TipRanks | Why Rhythm Pharmaceuticals Stock Is Suddenly Surging - TipRanks |
| 2024-02-22 | -9.6% | legal | SEC EDGAR | RYTM 8-K: 2.02, 8.01 (SEC Filing) |
| 2025-12-11 | +9.2% | news | Seeking Alpha | Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster |
| 2025-12-11 | +9.2% | earnings | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript |
| 2025-12-11 | +9.2% | news | Seeking Alpha | Rhythm advances lead asset into late-stage trial in Prader-Willi syndrome |
| 2025-12-11 | +9.2% | legal | SEC EDGAR | RYTM 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-12-11 | +9.2% | analyst | Investing.com | Morgan Stanley raises Rhythm Pharmaceuticals stock price target to $150 - Investing.com |
| 2025-12-11 | +9.2% | news | Investor's Business Daily | Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win - Investor's Business Daily |
| 2025-12-11 | +9.2% | news | Stocktwits | Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder - Stocktwits |
| 2025-12-11 | +9.2% | news | Seeking Alpha | Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster (RYTM) - Seeking Alpha |
| 2024-01-04 | -9.2% | legal | SEC EDGAR | RYTM 8-K: 1.01, 3.02and8.01 (SEC Filing) |
| 2023-03-10 | -7.2% | legal | SEC EDGAR | RYTM 8-K: 8.01 (SEC Filing) |
| 2026-03-26 | -6.9% | news | MT Newswires | Rhythm Pharmaceuticals Receives Positive Opinion From European Medicines Agency to Expand Imcivree Treatment |
| 2026-03-26 | -6.9% | M&A | GlobeNewswire | Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment |
| 2026-03-26 | -6.9% | news | Seeking Alpha | Rhythm Pharma wins EU backing to expand Imcivree label |
| 2026-03-26 | -6.9% | legal | SEC EDGAR | RYTM 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-03-26 | -6.9% | news | Stock Titan | EU panel backs Rhythm drug for obesity and hunger after brain injury - Stock Titan |
| 2026-01-09 | +6.8% | earnings | Seeking Alpha | Rhythm Pharma sees Q4 net product revenues from global sales of IMCIVREE to be about $57M |
| 2026-01-09 | +6.8% | legal | SEC EDGAR | RYTM 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2026-01-09 | +6.8% | earnings | Stocktwits | RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits |
| 2024-04-01 | -6.8% | legal | SEC EDGAR | RYTM 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-11-03 | -6.7% | earnings | Seeking Alpha | Rhythm Pharmaceuticals Q3 2025 Earnings Preview |
| 2025-11-03 | -6.7% | earnings | DirectorsTalk Interviews | Rhythm Pharmaceuticals (RYTM) Stock Analysis: An Investor’s Look at a Biotech with 66.8% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews |
| 2023-05-02 | -6.6% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2026-03-23 | -6.3% | analyst | Investing.com | H.C. Wainwright raises Rhythm Pharmaceuticals stock price target on FDA approval - Investing.com |
| 2026-02-02 | +6.0% | news | The Motley Fool | This High-Flying Growth Stock Is Hiding in Plain Sight - The Motley Fool |
| 2026-03-20 | -5.6% | legal | Seeking Alpha | Rhythm Pharma higher after FDA label expansion for lead drug |
| 2026-03-20 | -5.6% | M&A | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript |
| 2026-03-20 | -5.6% | legal | SEC EDGAR | RYTM 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-03-20 | -5.6% | news | Investor's Business Daily | Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo 'Have Fallen Flat' - Investor's Business Daily |
| 2026-03-20 | -5.6% | news | Yahoo Finance | Rhythm Pharmaceuticals (RYTM) Reports Phase 3 EMANATE Trial Topline Results for Setmelanotide - Yahoo Finance |
| 2026-03-20 | -5.6% | legal | Investing.com | Rhythm Pharmaceuticals stock jumps on FDA approval - Investing.com |
| 2026-03-20 | -5.6% | legal | Seeking Alpha | Rhythm Pharma wins FDA label expansion for lead drug (RYTM) - Seeking Alpha |
| 2026-03-20 | -5.6% | legal | StocksToTrade | **Rhythm Pharmaceuticals Surges with Significant Market Moves After FDA Expansion** - StocksToTrade |
| 2026-03-20 | -5.6% | M&A | Stock Titan | Rhythm Pharmaceuticals (Nasdaq: RYTM) gains FDA OK for IMCIVREE in acquired hypothalamic obesity - Stock Titan |
| 2026-03-20 | -5.6% | legal | Investing.com South Africa | Rhythm Pharmaceuticals stock jumps on FDA approval By Investing.com - Investing.com South Africa |
| 2026-03-20 | -5.6% | analyst | GuruFocus | Rhythm Pharmaceuticals (RYTM) Receives Buy Rating and Raised Pri - GuruFocus |
| 2026-03-20 | -5.6% | analyst | GuruFocus | RYTM: Citigroup Raises Price Target on Rhythm Pharmaceuticals | - GuruFocus |
| 2025-11-05 | -5.5% | earnings | Seeking Alpha | Rhythm Pharmaceuticals, Inc. 2025 Q3 - Results - Earnings Call Presentation |
| 2025-11-05 | -5.5% | M&A | Seeking Alpha | Rhythm Pharmaceuticals anticipates IMCIVREE launch in acquired hypothalamic obesity with $416M cash position |
| 2025-11-05 | -5.5% | earnings | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript |
| 2025-11-05 | -5.5% | earnings | Yahoo Finance | Rhythm Pharmaceuticals (RYTM): Losses Have Averaged 18.8% Growth Annually; Revenue Forecast +45.8% Heading Into Earnings - Yahoo Finance |
| 2026-02-26 | -5.4% | expansion | Seeking Alpha | Rhythm anticipates $385M–$415M in 2026 non-GAAP operating expenses as HO launch preparations accelerate |
| 2026-02-26 | -5.4% | earnings | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript |
| 2026-02-26 | -5.4% | earnings | Seeking Alpha | Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.07, revenue of $57.3M beats by $1.09M |
| 2026-02-26 | -5.4% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | -5.4% | earnings | Yahoo Finance | Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance |
| 2025-02-26 | +5.4% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2026-03-18 | +4.6% | expansion | Yahoo Finance | Rhythm Pharmaceuticals (RYTM) PT Increased From $136 to $143 at Wells Fargo on IMCIVREE Launch Optimism - Yahoo Finance |
| 2026-03-18 | +4.6% | news | Yahoo Finance | A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Share Weakness And Strong Long Term Returns - Yahoo Finance |
| 2026-03-18 | +4.6% | analyst | GuruFocus | HC Wainwright & Co. Lowers Price Target for Rhythm Pharmaceutica - GuruFocus |
| 2021-09-02 | -4.4% | legal | SEC EDGAR | RYTM 8-K: 5.02 and 7.01 (SEC Filing) |
| 2026-04-07 | -4.3% | analyst | MT Newswires | RBC Capital Adjusts Price Target on Rhythm Pharmaceuticals to $136 From $130, Maintains Outperform Rating |
| 2026-04-07 | -4.3% | news | simplywall.st | Why Rhythm Pharmaceuticals (RYTM) Is Up 12.6% After EU IMCIVREE Expansion Boost and Board Refresh – And What's Next - simplywall.st |
| 2025-05-07 | -4.3% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2024-06-17 | -4.3% | legal | SEC EDGAR | RYTM 8-K: 8.01 (SEC Filing) |
| 2026-03-22 | -4.3% | M&A | Simply Wall St. | How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity |
| 2026-03-22 | -4.3% | M&A | Yahoo Finance | How Investors May Respond To Rhythm Pharmaceuticals (RYTM) FDA Win For IMCIVREE In Acquired Hypothalamic Obesity - Yahoo Finance |
| 2025-11-08 | -4.2% | executive | The Motley Fool | Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million - The Motley Fool |
| 2025-12-30 | -4.0% | legal | TechStock² | Rhythm Pharmaceuticals (RYTM) stock falls today as biotech weakens; FDA decision stays in focus - TechStock² |
| 2026-03-17 | -4.0% | news | Seeking Alpha | Rhythm Pharma down after late-stage trial setback for lead asset in rare obesity disorders |
| 2026-03-17 | -4.0% | news | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial - Slideshow |
| 2026-03-17 | -4.0% | news | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial Transcript |
| 2026-03-17 | -4.0% | earnings | Investor's Business Daily | Rhythm Pharmaceuticals Misses The Beat In Obesity, But There's A Caveat - Investor's Business Daily |
| 2026-03-17 | -4.0% | news | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Topline Results and Insights from Phase 3 EMANATE Trial - Slideshow (NASDAQ:RYTM) 2026-03-17 - Seeking Alpha |
| 2026-03-17 | -4.0% | earnings | Investing.com | Needham cuts Rhythm Pharmaceuticals stock price target on trial miss - Investing.com |
| 2026-03-17 | -4.0% | executive | Benzinga | Rhythm Pharmaceuticals Rare Obesity Drug Study Disappoints - Benzinga |
| 2026-03-17 | -4.0% | analyst | GuruFocus | RYTM: Morgan Stanley Lowers Price Target to $136 While Maintaini - GuruFocus |
| 2026-03-03 | -4.0% | analyst | Investing.com | Jefferies reiterates Rhythm Pharmaceuticals stock rating on trial outlook - Investing.com |
| 2026-03-19 | +3.8% | legal | Stock Titan | First FDA-approved drug for rare weight-gain disorder clears in US - Stock Titan |
| 2026-03-19 | +3.8% | news | TipRanks | Why Rhythm Pharmaceuticals Stock Is Sliding Today - TipRanks |
| 2025-01-10 | -3.8% | legal | SEC EDGAR | RYTM 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2026-03-27 | -3.6% | news | Stock Titan | Vanguard disaggregates holdings; reports 0 shares in Rhythm Pharmaceuticals (NASDAQ: RYTM) - Stock Titan |
| 2024-07-10 | +3.6% | legal | SEC EDGAR | RYTM 8-K: 8.01 and (SEC Filing) |
| 2025-10-09 | +3.6% | news | Investor's Business Daily | Rhythm Pharma Stock Gears Up For Its Next Move - Investor's Business Daily |
| 2026-04-20 | -3.4% | analyst | Cổng thông tin điện tử tỉnh Tây Ninh | Rhythm Pharmaceuticals (RYTM) Stock: Mistakes to Avoid (Technical Strength) 2026-04-20 - Strong Buy Rating - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-20 | -3.4% | news | Cổng thông tin điện tử tỉnh Lào Cai | Rhythm Pharmaceuticals (RYTM) Stock: Mistakes to Avoid (Technical Strength) 2026-04-20 - Crowd Sentiment Stocks - Cổng thông tin điện tử tỉnh Lào Cai |
| 2024-04-16 | -3.3% | legal | SEC EDGAR | RYTM 8-K: 1.01, 3.03, 5.03, 8.01 (SEC Filing) |
| 2025-12-12 | -3.1% | news | Yahoo Finance | Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally? - Yahoo Finance |
| 2025-12-12 | -3.1% | analyst | Investing.com | Rhythm Pharmaceuticals stock jumps as Goldman Sachs raises price target on PWS study - Investing.com |
| 2023-12-06 | +2.9% | legal | SEC EDGAR | RYTM 8-K: 8.01 (SEC Filing) |
| 2021-12-08 | +2.9% | legal | SEC EDGAR | RYTM 8-K: 1.01 (SEC Filing) |
| 2024-02-29 | -2.8% | legal | SEC EDGAR | RYTM 8-K: 1.01 and (SEC Filing) |
| 2026-02-27 | -2.8% | earnings | Seeking Alpha | Rhythm Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation |
| 2026-02-27 | -2.8% | earnings | simplywall.st | Rhythm Pharmaceuticals (RYTM) Posts Q4 Revenue Gain That Challenges Bearish Cash Burn Narrative - simplywall.st |
| 2026-02-27 | -2.8% | analyst | Investing.com | Citizens raises Rhythm Pharmaceuticals stock price target on HO approval outlook - Investing.com |
| 2026-03-02 | -2.6% | legal | SEC EDGAR | RYTM 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-03-02 | -2.6% | news | Benzinga | Why Is Rhythm Pharmaceuticals Stock Trading Higher Today? - Rhythm Pharmaceuticals (NASDAQ:RYTM) - Benzinga |
| 2026-03-02 | -2.6% | analyst | Investing.com | Citizens reiterates Rhythm Pharmaceuticals stock rating on Japan opportunity - Investing.com |
| 2023-08-08 | +2.5% | legal | SEC EDGAR | RYTM 8-K: 5.02 (SEC Filing) |
| 2025-11-07 | -2.5% | legal | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Extension of PDUFA Goal Date for Setmelanotide in Hypothalamic Obesity Transcript |
| 2025-11-07 | -2.5% | legal | Seeking Alpha | Rhythm pharma down as FDA extends review period for Imcivree label expansion |
| 2025-11-07 | -2.5% | legal | SEC EDGAR | RYTM 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-11-07 | -2.5% | analyst | simplywall.st | The Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Third-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st |
| 2025-11-07 | -2.5% | legal | Seeking Alpha | Rhythm pharma down as FDA extends review period for Imcivree label expansion - Seeking Alpha |
| 2025-11-07 | -2.5% | legal | Investing.com | Rhythm Pharmaceuticals stock falls after FDA extends review period - Investing.com |
| 2025-07-10 | -2.5% | news | Yahoo Finance | Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock - Yahoo Finance |
| 2025-07-10 | -2.5% | earnings | Yahoo Finance | RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data - Yahoo Finance |
| 2025-07-10 | -2.5% | earnings | simplywall.st | Revenues Not Telling The Story For Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) After Shares Rise 33% - simplywall.st |
| 2026-03-01 | +2.3% | news | Yahoo Finance | A Look At Rhythm Pharmaceuticals (RYTM) Valuation After Recent Pullback In Share Price - Yahoo Finance |
| 2026-03-01 | +2.3% | M&A | Stock Titan | Obesity drug shows 18.8% BMI edge, backing first FDA bid in acquired HO - Stock Titan |
| 2026-02-06 | -2.3% | executive | Investing.com | Smith, Rhythm Pharmaceuticals CFO, sells $702k in RYTM stock - Investing.com |
| 2025-11-10 | -2.2% | news | Stock Titan | Rhythm Pharma (NASDAQ: RYTM) presents 27.1% BMI drop with setmelanotide plus GLP-1 - Stock Titan |
| 2026-01-01 | -2.1% | news | AD HOC NEWS | Rhythm Pharmaceuticals stock: can RYTM’s biotech story keep up with its rally? - AD HOC NEWS |
| 2026-02-19 | -2.0% | earnings | Finviz | Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? - Finviz |
| 2026-02-19 | -2.0% | analyst | Benzinga | Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market - Benzinga |
| 2026-02-19 | -2.0% | news | GuruFocus | Insider Sell: Hunter Smith Sells Shares of Rhythm Pharmaceuticals Inc (RYTM) - GuruFocus |
| 2026-04-12 | +1.9% | news | Stock Traders Daily | Avoiding Lag: Real-Time Signals in (RYTM) Movement - Stock Traders Daily |
| 2025-06-27 | +1.9% | news | Seeking Alpha | Rhythm Pharmaceuticals: Growth Is Expected To Go Parabolic (NASDAQ:RYTM) - Seeking Alpha |
| 2026-04-09 | -1.8% | news | GlobeNewswire | Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 |
| 2026-04-09 | -1.8% | earnings | Stock Titan | Rhythm sets May 5 earnings call, CFO due at Needham event - Stock Titan |
| 2026-04-09 | -1.8% | news | ChartMill | Rhythm Pharmaceuticals to Report First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - ChartMill |
| 2026-04-01 | -1.6% | news | Zacks | Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength? |
| 2026-04-01 | -1.6% | news | Yahoo Finance | Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength? - Yahoo Finance |
| 2026-04-01 | -1.6% | news | qz.com | Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 12.6% Jump Turn into More Strength? - qz.com |
| 2025-09-30 | -1.3% | news | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Stifel Virtual Cardiometabolic Forum Transcript |
| 2024-08-06 | -1.3% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2026-03-09 | -1.3% | news | DirectorsTalk Interviews | Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Capitalizing on a 49.91% Potential Upside with Groundbreaking Biopharma Innovations - DirectorsTalk Interviews |
| 2026-03-09 | -1.3% | news | Investor's Business Daily | Stocks Flashing Renewed Technical Strength: Rhythm Pharmaceuticals - Investor's Business Daily |
| 2023-08-03 | +1.2% | legal | SEC EDGAR | RYTM 8-K: 5.02 and (SEC Filing) |
| 2026-04-13 | +1.2% | news | simplywall.st | Assessing Rhythm Pharmaceuticals (RYTM) Valuation After A Recent Share Price Pullback - simplywall.st |
| 2025-08-28 | +1.1% | legal | Yahoo Finance | FDA Accepts a New Drug Application From Rhythm Pharmaceuticals (RYTM) - Yahoo Finance |
| 2026-03-16 | -0.9% | news | Seeking Alpha | Rhythm Pharmaceuticals: Rare Genetic Obesity Player With Upcoming PDUFA |
| 2026-03-16 | -0.9% | earnings | Seeking Alpha | Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision |
| 2026-03-16 | -0.9% | legal | SEC EDGAR | RYTM 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-03-16 | -0.9% | news | Stock Titan | Trust for Rhythm Pharmaceuticals (RYTM) director receives 4,199 shares - Stock Titan |
| 2026-03-16 | -0.9% | analyst | Investing.com | Stifel reiterates Rhythm Pharmaceuticals stock rating at buy - Investing.com |
| 2026-03-16 | -0.9% | earnings | Stock Titan | Obesity drug trial misses goal, yet some patients cut BMI by 9.7% - Stock Titan |
| 2026-03-16 | -0.9% | earnings | Seeking Alpha | Rhythm Pharmaceuticals Q4 Beat Sets Stage For March 20th PDUFA Decision (NASDAQ:RYTM) - Seeking Alpha |
| 2026-03-16 | -0.9% | news | Seeking Alpha | Rhythm Pharmaceuticals: Rare Genetic Obesity Player With Upcoming PDUFA (NASDAQ:RYTM) - Seeking Alpha |
| 2026-03-16 | -0.9% | news | GuruFocus | Rhythm Pharmaceuticals (RYTM) Shares Results from EMANATE Trial - GuruFocus |
| 2022-11-08 | -0.9% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2025-02-28 | -0.9% | legal | SEC EDGAR | RYTM 8-K: 8.01 (SEC Filing) |
| 2026-02-25 | -0.9% | earnings | Seeking Alpha | Rhythm Pharmaceuticals Q4 2025 Earnings Preview |
| 2026-02-25 | -0.9% | analyst | Investor's Business Daily | Rhythm Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Benchmark - Investor's Business Daily |
| 2025-11-25 | -0.8% | M&A | Seeking Alpha | Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress |
| 2025-11-25 | -0.8% | news | Seeking Alpha | Rhythm Pharmaceuticals initiated with Buy at Citi on Imcivree's potential |
| 2023-11-07 | +0.8% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2026-02-23 | -0.8% | news | DirectorsTalk Interviews | Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 42.11% Upside Potential with a Strong Buy Consensus - DirectorsTalk Interviews |
| 2025-08-05 | -0.5% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2023-08-21 | +0.5% | legal | SEC EDGAR | RYTM 8-K: 8.01 (SEC Filing) |
| 2025-12-05 | -0.4% | legal | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Extension of PDUFA Goal Date for Setmelanotide in Hypothalamic Obesity - Slideshow |
| 2026-02-18 | +0.4% | earnings | Yahoo Finance | How The Rhythm Pharmaceuticals RYTM Story Is Shifting With Imcivree Revenue And New Targets - Yahoo Finance |
| 2026-04-05 | +0.3% | news | Simply Wall St. | How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments |
| 2026-04-04 | +0.3% | news | Yahoo Finance | How The Rhythm Pharmaceuticals (RYTM) Story Is Evolving After EMANATE And Imcivree Developments - Yahoo Finance |
| 2026-04-03 | +0.3% | news | GlobeNewswire | Rhythm Pharmaceuticals Announces Changes to Board of Directors |
| 2026-04-03 | +0.3% | legal | SEC EDGAR | RYTM 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-04-03 | +0.3% | news | Stock Titan | Rhythm Pharmaceuticals (RYTM) EVP converts RSUs, now holding 66,030 shares - Stock Titan |
| 2026-04-03 | +0.3% | news | Stock Titan | RHYTHM (RYTM) director receives 6,808 RSUs and 10,257 stock options - Stock Titan |
| 2026-04-03 | +0.3% | news | Stock Titan | Biotech veteran Kim Popovits joins Rhythm board as Ed Mathers leaves - Stock Titan |
| 2026-04-03 | +0.3% | news | Stock Titan | Rhythm Pharmaceuticals (RYTM) director Kimberly Popovits files initial Form 3 - Stock Titan |
| 2026-04-03 | +0.3% | news | Stock Titan | Kim Popovits joins Rhythm (NASDAQ: RYTM) board as Ed Mathers exits - Stock Titan |
| 2025-12-17 | -0.3% | earnings | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps - Slideshow |
| 2025-12-17 | -0.3% | analyst | Investing.com | Guggenheim raises Rhythm Pharmaceuticals stock price target on promising PWS data - Investing.com |
| 2025-07-11 | +0.3% | legal | SEC EDGAR | RYTM 8-K: 8.01 and (SEC Filing) |
| 2023-03-01 | -0.3% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2021-05-03 | +0.3% | legal | SEC EDGAR | RYTM 8-K: 2.02 and (SEC Filing) |
| 2026-03-24 | -0.3% | M&A | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity - Slideshow |
| 2026-03-24 | -0.3% | M&A | Seeking Alpha | Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity - Slideshow (NASDAQ:RYTM) 2026-03-24 - Seeking Alpha |
| 2026-04-23 | +0.2% | news | ChartMill | RYTM Technical Analysis | Trend, Signals & Chart Patterns | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill |
| 2026-04-23 | +0.2% | earnings | Xã Thanh Hà | RYTM (Rhythm Pharmaceuticals) tops Q4 2025 EPS estimates, posts 45.8 percent year-over-year revenue growth, shares dip 1.09 percent. - Popular Market Picks - Xã Thanh Hà |
| 2025-12-19 | -0.2% | legal | SEC EDGAR | RYTM 8-K: 5.02 (SEC Filing) |
| 2026-04-10 | -0.1% | news | simplywall.st | Is Rhythm Pharmaceuticals (RYTM) Still Attractive After A 48.9% One‑Year Share Price Gain - simplywall.st |
| 2026-04-26 | — | news | Insider Monkey | Billionaire Joe Edelman’s 5 Stock Picks with Huge Upside Potential - Insider Monkey |
| 2026-04-26 | — | news | MSN | Is this weight loss drug stock a buy after a new approval? - MSN |
| 2026-04-25 | — | earnings | MarketBeat | M&T Bank Corp Invests $9.20 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat |
| 2026-04-24 | — | news | Insider Monkey | Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now? |
| 2026-04-24 | — | news | Yahoo Finance | Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now? - Yahoo Finance |
| 2026-04-24 | — | news | Insider Monkey | Is Rhythm Pharmaceuticals, Inc. (RYTM) A Good Stock To Buy Now? - Insider Monkey |
| 2026-04-24 | — | earnings | MarketBeat | Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat |